Achieve Life Sciences is a specialty pharmaceutical company committed to addressing the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the α4β2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.  Achieve’s focus is to address the global smoking health epidemic by making cytisinicline widely available.

Recent News

More News

The Phase 3 ORCA-2 trial of cytisinicline has reached its enrollment target of 750 adult smokers. 

ORCA-2 is designed to evaluate the safety and efficacy of 3 mg cytisinicline dosed 3 times daily compared to placebo in adult cigarette smokers who want to quit.

The trial is currently being conducted at 17 sites in the U.S.

Learn More
Positive Phase 2b ORCA-1 Results Reported

ORCA-2 clinical trial site locations. Click image to enlarge.

In RAUORA study, led by Dr. Natalie Walker – Associate Professor at the University of Auckland, cytisinicline-treaded subjects experienced significantly fewer side effects and were 55% more likely to quit smoking compared to those who received Chantix®.

Chantix® is a registered trademark of Pfizer Inc.

  • RAUORA trial infographic

Achieve CSO, Dr. Anthony Clark, Presents Data on Cytisinicline MOA at SRNT-E Annual Meeting

Smoking is a global public health epidemic responsible for the loss of over 8 million lives annually.

cytisus

Cytisinicline

Cytisinicline is a plant-based smoking cessation treatment currently approved in Central and Eastern Europe.

Learn More
ORCA Program

Clinical Trials

ORCA: Ongoing Research of Cytisinicline for Addiction.

Learn More
invest

Investors

Achieve is a specialty pharmaceutical company focused global development of cytisinicline for smoking cessation.

Learn More

Smoking is the #1 cause of preventable deaths worldwide.

According to the Centers for Disease Control and Prevention (CDC), 70% of current smokers expressed desire to quit, 55% attempted to quit, only 7% succeeded in quitting in the past year.